Oxford BioMedica (LSE:OXB) has reported robust financial results for the first half of 2025, with revenues rising 44% to £73.2 million, driven by strong demand for its CDMO services. The company improved profitability, reducing its operating EBITDA loss, and strengthened its balance sheet through new financial facilities and share placements.
Strategic initiatives, including the expansion of US commercial-scale GMP capacity, are expected to support continued growth and further enhance Oxford BioMedica’s market position.
The company’s outlook is supported by positive earnings call insights and key corporate developments, signaling strategic growth and management confidence. Nevertheless, financial performance pressures and valuation considerations moderate the overall assessment.
About Oxford BioMedica
Oxford BioMedica is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies. The company provides services across various vector types, focusing on late-stage and commercial programs, and is recognized for its innovation and high-quality manufacturing, establishing it as a leader in the cell and gene therapy sector.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.









